Efficacy of a dehydrated porcine placental extracellular matrix for the treatment of multiple chronic wound types in a private practice model: a retrospective feasibility study
DOI:
https://doi.org/10.63676/1p43y632Keywords:
porcine placental extracellular matrix, chronic wound, percentage area reduction, complete closure, Real-world evidenceAbstract
Objective: To assess real-world effectiveness of Innovamatrix™, a dehydrated porcine placental extracellular matrix (PPECM), in chronic wounds refractory to 30 days of optimized standard-of-care (SOC) therapy.
Methods: Multicenter retrospective analysis of 72 chronic wounds (18 diabetic foot ulcers (DFUs), 4 venous leg ulcers (VLUs), 12 pressure injuries, 38 open wounds) in 66 patients treated with sequential PPECM applications (between October 2023 and June 2025). All wounds showed <50% area reduction during SOC run-in and met Medicare Local Coverage Determination (LCD) eligibility. Primary endpoint focused on complete re-epithelialization (99.99% to 100% percent area reduction (PAR)). Secondary endpoints included PAR, applications to closure, and time-to-closure.
Results: Wounds presented with a mean baseline area of 9.75 ± 15.97 cm2 and achieved a mean PAR of 85.92%. Complete closure occurred in 46/72 wounds (63.9%): 61.1% of DFUs healed, 50.0% pressure injuries healed, 76.3% open wounds healed, and 0% VLUs healed. Among healed wounds, the median number of applications to closure was 6 (mean 6.28 ± 3.58) with open wounds healing the fastest (median 4). Paired t-test showed statistically significant area reductions (t(71)=10.47, p<0.001; Cohen’s d=0.65). Etiology-specific effect sizes were moderate to large. Kaplan-Meier median time-to-closure was 43 days (95% CI 36-56).
Conclusion: In complex, previously non-responsive, chronic wounds, PPECM achieved a 63.9% complete closure rate and 85.92% mean PAR. Healing outcomes in pressure injuries and open wounds were comparable or superior to DFUs. These data support broader, etiology-agnostic use of PPECM as an effective advanced therapy when combined with comprehensive SOC.
References
Soong E, Marcinek B, Taylor C et al. Real-world use of a decellularized porcine placental extracellular matrix in hard-to-heal wounds: a retrospective, single-center study. J Clin Med. 2025;14(19):6823. https://doi.org/10.3390/jcm14196823 DOI: https://doi.org/10.3390/jcm14196823
Marcinek B, Levinson J, Nally S et al. Comparative effectiveness of porcine placental extracellular matrix against other cellular, acellular and matrix-like products in diabetic foot ulcers from the Medicare database. J Comp Eff Res. 2025;14(9):e250092. https://doi.org/10.57264/cer-2025-0092 DOI: https://doi.org/10.57264/cer-2025-0092
Fife C, LeBoutillier B, Taylor C et al. Real-world use and outcomes of hard-to-heal wounds managed with porcine placental extracellular matrix. Cureus. 2024;16(12):e76262. https://doi.org/10.7759/cureus.76262 DOI: https://doi.org/10.7759/cureus.76262
Banerjee J, Lasiter A, Nherera L. Systematic review of cellular, acellular, and matrix-like products and indirect treatment comparison between cellular/acellular and amniotic/nonamniotic grafts in the management of diabetic foot ulcers. Adv Wound Care (New Rochelle). 2024;13(12):639–651. https://doi.org/10.1089/wound.2023.0075 DOI: https://doi.org/10.1089/wound.2023.0075
Ragsdale LB, Sarhaddi D, Nathan C. Novel use of wound matrix in mastopexy complicated by pyoderma gangrenosum. Aesthet Surg J Open Forum. 2023:ojad085. https://doi.org/10.1093/asjof/ojad085 DOI: https://doi.org/10.1093/asjof/ojad085
Centers for Medicare and Medicaid Services. Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Medicare Coverage Database. Accessed December 12, 2025. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39870&ver=4
Carpenter S, Ferguson A, Bahadur D et al. Efficacy of cellular and/or tissue-based product applications on all non-pressure injury chronic wound types in a Medicare private practice model. Wounds. 2025;37(8):292–304. https://doi.org/10.25270/wnds/25005 DOI: https://doi.org/10.25270/wnds/25005
Arnold J, Arm DM. Processed microvascular tissue improves healing in a case series of challenging wounds. Journal of Clinical and Translational Research. 2024;10(5):307–316. https://doi.org/10.36922/jctr.24.00059 DOI: https://doi.org/10.36922/jctr.24.00059
Oltmann M, Kyle D, Gilbert TJ et al. Clinical outcomes of lyophilised human amnion/chorion membrane in treatment of hard-to-heal diabetic foot ulcers in complex cases: a case series. J Wound Care. 2025;34(3):187–194. https://doi.org/10.12968/jowc.2025.0022 DOI: https://doi.org/10.12968/jowc.2025.0022
Boynton SR, Butuci M, Forsyth RA et al. Bovine-derived collagen matrix as an adjunct in stage 3 pressure injuries: a case series of lower extremity wounds. J Wound Care. 2025;34(9):708–716. https://doi.org/10.12968/jowc.2025.0254 DOI: https://doi.org/10.12968/jowc.2025.0254
Cui J, Wang M, Lin C et al. Exploring machine learning strategies for single-cell transcriptomic analysis in wound healing. Burns Trauma. 2025;13:tkaf032. https://doi.org/10.1093/burnst/tkaf032 DOI: https://doi.org/10.1093/burnst/tkaf032
Narayan N, Shivannaiah C, Gowda S. Evaluating the efficacy of high-purity type I collagen-based skin substitute versus dehydrated human amnion/chorion membrane in the treatment of venous leg ulcers: a randomized controlled clinical trial. Cureus, 2025;17(7):e89031. https://doi.org/10.7759/cureus.89031 DOI: https://doi.org/10.7759/cureus.89031
Published
Data Availability Statement
The data in this study are not available to readers.
Issue
Section
License
Copyright (c) 2026 International Journal of Tissue Repair
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
